Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups

被引:132
作者
Lee, SJ
Usmani, KA
Chanas, B
Ghanayem, B
Xi, T
Hodgson, E
Mohrenweiser, HW
Goldstein, JA
机构
[1] NIEHS, Human Metab Sect, NIH, Res Triangle Pk, NC 27709 USA
[2] NIEHS, Metab Exposure Markers Grp, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA
[3] N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA
[4] Lawrence Livermore Natl Lab, Livermore, CA USA
来源
PHARMACOGENETICS | 2003年 / 13卷 / 08期
关键词
CYP3A5; polymorphisms; human; drug metabolism; SNP; cDNA expression system;
D O I
10.1097/00008571-200308000-00004
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives Genetic polymorphisms of cytochromes P450 (CYPs) are a principal reason for inter-individual variations in the metabolism of therapeutic drugs and environmental chemicals in humans. The present study identifies 34 single nucleotide polymorphisms (SNPs) of CYP3A5 including 27 previously unidentified SNPs by direct sequencing of the exons, intron-exon junctions and 5'-upstream region of CYP3A5 from 92 racially diverse individuals (24 Caucasians, 24 Africans, 24 Asians, and 20 individuals of unknown racial origin). Results Four new CYP3A5 SNPs produced coding changes: R28C, L82R, A337T, and F446S. CYP3A5 R28C occurred in African populations (allelic frequency of 4%). CYP3A5 A337T occurred in Asians (2% allelic frequency), CYP3A5 L82R (occurred in the racially unidentified group) and CYP3A5 F446S (identified in Caucasians with a 2% allelic frequency) were on an allele containing the splice change g.6986A>G known as CYP3A5*3. The newly identified allelic proteins were constructed by site-directed mutagenesis, expressed in Escherichia coli and purified. CYP3A5 L82R was expressed only as denatured CYP420, suggesting it may be unstable. CYP3A5*1 exhibited the highest maximal clearance for testosterone followed by CYP3A5 A337T>CYP3A5 R28C CYP3A5 F446S. CYP3A5*1 exhibited a higher V-max for nifedipine oxidation than CYP3A5 A337T>CYP3A5 R28Cmuch greater thanCYP3A5 F446S. CYP3A5 A337T and CYP3A5 R28C exhibited a 42-64% lower V-max for nifedipine oxidation than CYP3A5*1. CYP3A5 F446S exhibited a >95% decrease in the intrinsic clearance for both 6beta-hydroxytestosterone and nifedipine oxidation. Conclusion This study identifies four new potentially defective coding alleles. CYP3A5 F446S is predicted to be more catalytically defective than the splice change alone. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:461 / 472
页数:12
相关论文
共 47 条
  • [1] Antonarakis SE, 1998, HUM MUTAT, V11, P1
  • [2] AOYAMA T, 1989, J BIOL CHEM, V264, P10388
  • [3] EXPRESSION AND ENZYMATIC-ACTIVITY OF RECOMBINANT CYTOCHROME-P450 17-ALPHA-HYDROXYLASE IN ESCHERICHIA-COLI
    BARNES, HJ
    ARLOTTO, MP
    WATERMAN, MR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (13) : 5597 - 5601
  • [4] PARTICULAR ABILITY OF CYTOCHROMES P450 3A TO FORM INHIBITORY P450-IRON-METABOLITE COMPLEXES UPON METABOLIC OXIDATION OF AMINODRUGS
    BENSOUSSAN, C
    DELAFORGE, M
    MANSUY, D
    [J]. BIOCHEMICAL PHARMACOLOGY, 1995, 49 (05) : 591 - 602
  • [5] MEMBRANE TOPOLOGY OF THE MAMMALIAN P450-CYTOCHROMES
    BLACK, SD
    [J]. FASEB JOURNAL, 1992, 6 (02) : 680 - 685
  • [6] Characterization of single-nucleotide polymorphisms in coding regions of human genes
    Cargill, M
    Altshuler, D
    Ireland, J
    Sklar, P
    Ardlie, K
    Patil, N
    Lane, CR
    Lim, EP
    Kalyanaraman, N
    Nemesh, J
    Ziaugra, L
    Friedland, L
    Rolfe, A
    Warrington, J
    Lipshutz, R
    Daley, GQ
    Lander, ES
    [J]. NATURE GENETICS, 1999, 22 (03) : 231 - 238
  • [7] Cascorbi I, 1996, CANCER RES, V56, P4965
  • [8] Chou FC, 2001, DRUG METAB DISPOS, V29, P1205
  • [9] A DNA polymorphism discovery resource for research on human genetic variation
    Collins, FS
    Brooks, LD
    Chakravarti, A
    [J]. GENOME RESEARCH, 1998, 8 (12) : 1229 - 1231
  • [10] 4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER
    COOMBES, RC
    GOSS, P
    DOWSETT, M
    GAZET, JC
    BRODIE, A
    [J]. LANCET, 1984, 2 (8414) : 1237 - 1239